[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thyroid-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thyroid-diseases":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,43,71,111,135,156,187,212,242,280,311,334,371,400],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":19,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100577856","postoperative-pain-of-robotic-endoscopic-and-open-lateral-neck-dissection-100577856",false,"NCT06803732","Postoperative Pain of Robotic, Endoscopic and Open Lateral Neck Dissection","Inclusion Criteria:\n\n* Patients underwent lateral neck dissection via robotic, endoscopic or open approach\n* Clinical diagnosis of differentiated thyroid cancer\n* Clinical diagnosis of metastatic lateral lymph nodes\n\nExclusion Criteria:\n\n* Participants with distant metastasis\n* Participants with history of neck surgery or radiation\n* Participants with vocal fold fixation by preoperative fibrolaryngoscope","ALL",{"count":17,"type":18},600,"ESTIMATED","6 Months","OBSERVATIONAL","Postoperative pain is a good indicator to confirm the advantages of the surgical methods in the era of minimally invasive surgery. Lateral neck dissection requires extensive dissection which may leads to postoperative numbness and pain. Robotic thyroid surgery has the advantage of precise and careful dissection and avoid the L-shape incision in the open approach. The study aims to explore the pain intensity and severity of lateral neck dissection on operation day, postoperative month 1 and postoperative month 3 among the robotic, endoscopic and open approach.",[23,24,25],"Pain, Postoperative","Thyroid Diseases","Surgery",[27,28,29],"Lateral neck dissection","Robotic thyroid surgery","Minimally invasive surgery","RECRUITING","2026-06-20",{"date":33,"type":34},"2026-06-24","ACTUAL",{"date":36,"type":34},"2024-11-01",{"date":38,"type":18},"2027-12-31",{"name":40,"class":41},"Shanghai 6th People's Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":67,"leadSponsor":69,"locationsCount":42},"100638805","computer-vision-based-recognition-of-parathyroid-glands-and-recurrent-laryngeal-nerves-in-endoscopic-surgery-100638805","NCT07628543","Computer Vision-Based Recognition of Parathyroid Glands and Recurrent Laryngeal Nerves in Endoscopic Surgery","Prospective Multicenter Model Validation Study of the PTAIR Computer Vision Model for Recognition of Parathyroid Glands and Recurrent Laryngeal Nerves During Endoscopic Thyroid Surgery","PTAIR","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Patients with benign or malignant thyroid disease who are scheduled to undergo endoscopic thyroid surgery.\n3. Standardized recorder-based intraoperative video collection is planned during surgery.\n4. Patients agree to intraoperative video recording, de-identification, and research use.\n5. Basic perioperative clinical data are available.\n6. The participating center is able to follow the standardized procedures for video collection, data upload, data security, and annotation quality control.\n\nExclusion Criteria:\n\n1. Refusal to provide informed consent.\n2. Patients scheduled to undergo conventional open thyroid surgery.\n3. Standardized recorder-based intraoperative video collection cannot be performed.\n4. Intraoperative video quality is insufficient for model analysis or expert review.\n5. Key surgical phases are missing from the video recording.\n6. Expert annotation or review of the parathyroid glands or recurrent laryngeal nerves cannot be completed.\n7. Video de-identification fails.\n8. Severe missing perioperative clinical data.\n9. Other conditions judged by the investigators to be unsuitable for study inclusion.",{"count":52,"type":18},100,"This study aims to evaluate the performance of the PTAIR computer vision model for recognizing parathyroid glands and recurrent laryngeal nerves during endoscopic thyroid surgery. Multicenter intraoperative endoscopic surgery videos will be prospectively collected. Using the video recorder timeline as the unified time reference, the first recognition time of parathyroid glands and recurrent laryngeal nerves by PTAIR, junior physicians, and senior physicians will be recorded during surgery. The continuous recognition time of parathyroid glands and recurrent laryngeal nerves by PTAIR will also be recorded.\n\nThis study focuses on the recognition performance of PTAIR in real-world multicenter endoscopic thyroid surgery settings. At this stage, PTAIR will not be used to guide intraoperative surgical decision-making, and the study will not evaluate the effect of PTAIR on clinical outcomes. The collected video data will be used to assess the performance of PTAIR under different centers, surgeons, equipment conditions, and surgical field conditions, and may provide data support for future model optimization.",[24,55],"Thyroid Neoplasms",[49,57,58,59,60,61],"Computer Vision","Endoscopic Thyroid Surgery","Parathyroid Gland Recognition","Recurrent Laryngeal Nerve Recognition","Model Validation","NOT_YET_RECRUITING","2026-06-01",{"date":65,"type":34},"2026-06-05",{"date":63,"type":18},{"date":68,"type":18},"2028-05-31",{"name":70,"class":41},"Fujian Medical University",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":15,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":91,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":106,"completionDateStruct":107,"leadSponsor":109,"locationsCount":42},"100640349","niraf-guided-parathyroid-identification-during-thyroidectomy-100640349","NCT07617584","NIRAF-Guided Parathyroid Identification During Thyroidectomy","Near-Infrared Autofluorescence-Guided Parathyroid Identification During Thyroidectomy","Inclusion Criteria:\n\n* Age 18 years or older.\n* For Component A: planned thyroidectomy of any extent with an intact specimen available for ex vivo evaluation.\n* For Component B: planned total or completion thyroidectomy.\n* Ability to provide written informed consent before surgery.\n* Willingness to comply with routine postoperative laboratory testing and follow-up when feasible.\n\nExclusion Criteria:\n\n* Known pre-existing hypoparathyroidism or prior parathyroid surgery.\n* Severe chronic kidney disease or end-stage renal disease expected to substantially confound calcium and parathyroid hormone interpretation, as defined by the site investigator.\n* Pregnancy.\n* For Component B only: gross nodal disease or a surgical plan requiring extensive nodal packet dissection in the current study phase.\n* Any condition that, in the judgment of the investigator, would make participation unsafe or compromise protocol adherence.","18 Years",{"count":80,"type":18},280,"INTERVENTIONAL",[83],"NA","This is a single-site, two-component prospective study evaluating whether near-infrared autofluorescence (NIRAF) imaging can improve intraoperative identification of parathyroid glands during thyroidectomy and reduce postoperative hypocalcemia.\n\nThe investigational platform is a modified wearable stereoscopic goggle system configured for label-free NIRAF imaging. Parathyroid tissue is excited with near-infrared light at approximately 780 nm and emits autofluorescence centered near 800 nm. No injected dye or external contrast agent is used. The goggles are used only during a brief mapping interval after thyroid exposure and for ex vivo interrogation of the resected thyroid specimen.\n\nComponent A is a prospective observational run-in validation cohort of 30 adults undergoing thyroidectomy of any extent. NIRAF-positive foci on the intact thyroidectomy specimen are suture-marked and correlated with targeted pathology.\n\nComponent B is a randomized clinical study of 250 adults undergoing total or completion thyroidectomy. Participants are randomized 1:1 to standard surgery or standard surgery plus brief in vivo NIRAF mapping, ex vivo specimen interrogation, and rescue autotransplantation when indicated. The primary outcome for Component B is transient biochemical hypocalcemia on postoperative day 1, defined using albumin-corrected serum calcium.",[86,87,24,88,89,90],"Hypocalcemia","Hypoparathyroidism","Goiter, Nodular","Thyroid Nodule","Thyroidectomy",[92,93,94,95,90,96,97,98,99,100,101,102,103],"Near-Infrared Autofluorescence","NIRAF","Parathyroid Identification","Parathyroid Preservation","Completion Thyroidectomy","Total Thyroidectomy","Postoperative Hypocalcemia","Intact Parathyroid Hormone","iPTH","Rescue Autotransplantation","Wearable Imaging","Post-thyroidectomy hypocalcemia","2026-05-29",{"date":63,"type":34},{"date":63,"type":18},{"date":108,"type":18},"2029-12-01",{"name":110,"class":41},"Ss. Cyril and Methodius University of Skopje",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":117,"targetDuration":19,"studyType":20,"phases":4,"briefSummary":119,"conditions":120,"keywords":124,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":134,"locationsCount":42},"100572211","surgical-competency-for-robot-assisted-thyroidectomy-construction-and-validation-of-a-robotic-thyroidectomy-assessment-score-rtas-100572211","NCT06730321","Surgical Competency for Robot-Assisted Thyroidectomy: Construction and Validation of a Robotic Thyroidectomy Assessment Score (RTAS)","Inclusion Criteria:\n\n* Clinical diagnosis of differentiated thyroid cancer with a maximum diameter not exceeding 4 cm\n* Clinical diagnosis of benign thyroid nodules with a maximum diameter not exceeding 6 cm\n* Participants with high cosmetic expectations\n* Participants underwent robotic thyroidectomy without open conversion\n\nExclusion Criteria:\n\n* Participants with history of neck surgery or radiation\n* Participants with vocal fold fixation by preoperative fibrolaryngoscope\n* Participants with preoperative examination suggestive of distant invasion\n* Participants with fusion or fixed of lymph nodes in the neck",{"count":118,"type":18},200,"To develop and validate a structured scoring tool (robotic thyroidectomy assessment score, RTAS) for assessing and quantifying surgical performance in robotic thyroidectomy (RT).",[121,89,24,122,123],"Thyroid Cancer","Thyroid Cancer, Papillary","Thyroid Cancer, Follicular",[125,126,127],"Robotic thyroidectomy","Surgical competency","Robotic thyroidectomy assessment score","2026-05-02",{"date":130,"type":34},"2026-05-07",{"date":132,"type":34},"2024-12-12",{"date":38,"type":18},{"name":40,"class":41},{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":144,"conditions":145,"keywords":146,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":150,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":42},"100572870","renovated-prediction-model-for-difficult-transoral-and-submental-endoscopic-thyroidectomy-100572870","NCT06738888","Renovated Prediction Model for Difficult Transoral and Submental Endoscopic Thyroidectomy","Renovated Prediction Model for Difficult. Transoral and Submental Endoscopic Thyroidectomy","Inclusion Criteria:\n\n* Clinical diagnosis of differentiated thyroid cancer with a maximum diameter not exceeding 4 cm\n* Clinical diagnosis of benign thyroid nodule with a maximum diameter not exceeding 6 cm\n* Absence of suspicious lateral lymph nodes or distant metastases\n\nExclusion Criteria:\n\n* Participants with fusion or fixation of lymph nodes in the neck\n* Participants with history of neck surgery or radiation\n* Participants with vocal fold fixation by preoperative fibrolaryngoscope\n* Participants with preoperative examination suggestive of extrathyroidal invasion\n* Participants with a significantly restricted neck and\u002For jaw",{"count":143,"type":18},300,"The investigators have previously proposed a prediction model for difficult transoral and submental thyroidectomy through a retrospective study. In order to better promote transoral and submental endoscopic approach for thyroid surgery and to set up an appropriate training course, the investigators aim to renovate and validate the prediction model through a prospective study.",[121,24,89],[147,148,149],"Endoscopic thyroidectomy","Transoral and submental approach","Prediction model",{"date":130,"type":34},{"date":152,"type":34},"2024-05-01",{"date":154,"type":18},"2028-12-31",{"name":40,"class":41},{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":15,"minAge":78,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":81,"phases":166,"briefSummary":168,"conditions":169,"keywords":170,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":42},"100628481","phase-4-dexmedetomidine-for-improving-emergence-quality-in-thyroid-surgery-100628481","NCT07462195","Dexmedetomidine for Improving Emergence Quality in Thyroid Surgery","Effect of Perioperative Dexmedetomidine Infusion on Anesthetic Requirements and Quality of Emergence in Patients Undergoing Thyroid Surgery: A Randomized Controlled Trial","DEX-THYROID","Inclusion Criteria:\n\n* Age 18-65 years.\n* American Society of Anesthesiologists (ASA) physical status I-III.\n* Scheduled for elective thyroid surgery (thyroidectomy) under general anesthesia with endotracheal intubation.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Known hypersensitivity or contraindication to dexmedetomidine or study-related medications.\n* Clinically significant cardiac conduction abnormality or arrhythmia (e.g., second- or third-degree atrioventricular block without a pacemaker), severe bradyarrhythmia, or unstable cardiovascular disease.\n* Severe hepatic dysfunction or severe renal failure.\n* Pregnancy or breastfeeding.\n* Planned postoperative ICU admission or postoperative deterioration requiring ICU admission.\n* Major intraoperative complications (e.g., major bleeding requiring urgent hemostatic intervention, tracheal or esophageal injury, or recurrent laryngeal nerve injury identified intraoperatively).\n* Any condition that, in the investigator's judgment, would interfere with outcome assessment or increase risk (e.g., inability to reliably report pain scores or complete QoR-15).","65 Years",{"count":52,"type":18},[167],"PHASE4","Thyroid surgery requires smooth emergence from anesthesia to minimize coughing, hemodynamic fluctuations, and agitation during extubation, which may contribute to postoperative complications such as bleeding or cervical hematoma. Dexmedetomidine, a selective α2-adrenergic receptor agonist, has sedative, analgesic-sparing, and sympatholytic properties that may improve anesthetic stability and recovery quality.\n\nThis randomized controlled trial aims to evaluate the effectiveness of a continuous perioperative dexmedetomidine regimen initiated at induction of anesthesia and maintained during thyroid surgery.\n\nThe study will compare dexmedetomidine combined with standard balanced anesthesia versus standard anesthesia alone in terms of anesthetic requirements and emergence quality.\n\nThe primary hypothesis is that perioperative dexmedetomidine administration reduces anesthetic and opioid requirements and improves emergence quality by decreasing coughing during extubation and hemodynamic responses.",[24],[171,90,172,173,174,175,176,177],"Dexmedetomidine","General Anesthesia","Extubation Cough","Emergence Agitation","Postoperative Nausea and Vomiting","Anesthetic Requirement","Quality of Recovery","2026-04-12",{"date":180,"type":34},"2026-04-15",{"date":182,"type":34},"2026-04-13",{"date":184,"type":18},"2026-11-30",{"name":186,"class":41},"Bach Mai Hospital",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":15,"minAge":78,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":81,"phases":197,"briefSummary":199,"conditions":200,"keywords":201,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":42},"100422792","phase-3-contribution-of-icg-angiography-in-the-detection-of-parathyroids-and-the-prevention-of-hypoparathyroidism-post-total-thyroidectomy-100422792","NCT04785443","Contribution of ICG Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy","Contribution of Indocyanine Green Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy","HYPOCAAVI","Inclusion Criteria:\n\n* Patient having to undergo a total thyroidectomy\n* Signed consent\n* Patient beneficiary of a social security regimen\n\nExclusion Criteria:\n\n* Minor patient under 18 years old\n* Major patient protected by law or unable to give informed consent\n* Pregnant or breastfeeding woman\n* Thyroidectomy totalization\n* History of thyroid or parathyroid surgery\n* Participation refusal\n* Known allergy to ICG\n* Woman of child-bearing age not using adequate method of contraception",{"count":196,"type":18},242,[198],"PHASE3","* Hypoparathyroidism is the most common complication after a total thyroidectomy surgery. It becomes permanent after 6 months.\n* Untreated permanent hypoparathyroidism is a source of numerous complications in general and therefore requires lifelong replacement therapy resulting in a significant deterioration in quality of life.\n* The intraoperative use of indocyanine green (ICG) angiography has recently been described as a reliable means of detecting parathyroidism and predicting the risk of postoperative hypoparathyroidism.\n* This use could prove to be a way to preserve parathyroid in vivo and thus reduce post-operative hypoparathyroidism rates.",[24],[86,87,202],"Angiography","2026-03-18",{"date":205,"type":34},"2026-03-19",{"date":207,"type":34},"2021-06-22",{"date":209,"type":18},"2027-06-22",{"name":211,"class":41},"University Hospital, Brest",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":15,"minAge":78,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":81,"phases":221,"briefSummary":222,"conditions":223,"keywords":226,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":42},"100622388","safety-and-efficacy-of-ntp-in-thyroid-surgery-pilot-study-on-morbidity-prevention-and-adjuvant-oncological-control-100622388","NCT07382973","Safety and Efficacy of NTP in Thyroid Surgery: Pilot Study on Morbidity Prevention and Adjuvant Oncological Control","Evaluation of Non-Thermal Plasma as an Innovative Strategy for Optimizing Post-Surgical Wound Treatment in Patients of Thyroid Surgery: An Ethical and Clinical Approach","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Diagnosis of thyroid pathology requiring total or subtotal thyroidectomy.\n* Signed Informed Consent Form (ICF).\n* Patients capable of complying with the 12-week follow-up schedule.\n\nExclusion Criteria:\n\n* History of previous neck surgery or radiation therapy in the cervical area.\n* Known history of keloid formation or hypertrophic scarring.\n* Presence of active systemic or local infection at the time of surgery.\n* Patients with implanted electronic devices (e.g., pacemakers or defibrillators) due to the use of RF-based plasma.\n* Pregnancy or breastfeeding.\n* Concurrent use of systemic corticosteroids or immunosuppressive drugs that may impair wound healing.",{"count":220,"type":18},26,[83],"The goal of this clinical trial is to evaluate the therapeutic efficacy and safety of non-thermal plasma (NTP) as an adjuvant treatment for surgical bed decontamination and accelerated tissue repair in patients undergoing total thyroidectomy. The study aims to address the following objectives:\n\n* Does the intraoperative application of NTP to the surgical bed and closed incision promote accelerated tissue regeneration compared to conventional postoperative care?\n* Does NTP treatment reduce postoperative inflammatory response, pain intensity, and the incidence of site-specific complications (such as surgical site infection or seroma)?\n* What is the safety profile of helium-based NTP in the cervical anatomical region regarding neighboring neurovascular structures?\n\nParticipants will be randomized into two arms:\n\n1. The experimental group: Receiving a standardized application of helium-based NTP (at a frequency of 13.56 MHz) to the surgical bed prior to closure and subsequently to the sutured incision.\n2. The control group: Receiving standard-of-care surgical wound management.\n\nClinical follow-up will include quantitative assessment of healing rates, pain scales (VAS), and biochemical or clinical markers of inflammation at scheduled intervals (Days 1, 7, 15, and up to 12 weeks post-surgery).",[24,224,90,225],"Wound Healing","Surgical Wound Infection",[227,228,229,224,230,231,232],"Non-Thermal Plasma","Cold Plasma","Thyroid Surgery","Postoperative Pain","Adjuvant Therapy","Surgical Bed Decontamination","2026-02-05",{"date":235,"type":34},"2026-02-09",{"date":237,"type":34},"2025-08-20",{"date":239,"type":18},"2026-12-30",{"name":241,"class":41},"National Institute of Nuclear Research - Mexico",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":250,"conditions":251,"keywords":266,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":42},"100616152","generative-ai-impact-on-rheumatoid-arthritis-complications-diagnosis-100616152","NCT07301892","Generative AI Impact on Rheumatoid Arthritis Complications Diagnosis","Impact of Generative Artificial Intelligence on Diagnosing Rheumatoid Arthritis Complications","Inclusion Criteria:\n\n* Patients with an initial diagnosis of rheumatoid arthritis (RA).\n* All real-world RA inpatients admitted to our department.\n* Admission occurring within the real-world data study period.\n\nExclusion Criteria:\n\n* Patients subsequently confirmed not to have RA during the study.",{"count":52,"type":18},"Generative AI (GenAI) based on large language models (LLMs) is expected to improve the diagnosis and treatment of autoimmune diseases. We are studying how GenAI may affect the diagnosis of various complications of rheumatoid arthritis (RA). In a retrospective study using RA patients' EHR records, we will quantify physician adoption of GenAI predictions for RA complications and co-existing diseases. In a prospective observational study, we will assess the feasibility of using GenAI predictions as additional clinical information to help physicians make more complete diagnoses of RA complications and co-existing diseases, including complex, uncommon, or rare conditions.",[252,253,254,255,24,256,257,258,259,260,261,262,263,264,265],"Rheumatoid Arthritis (RA","Osteoporosis","Osteoarthritis","Interstitial Lung Disease","Cardiovascular Diseases","Pulmonary Complications","Sjogren's Syndrome","Liver Disorders","Renal Lesions","Vasculitis","Amyloidosis","Peripheral Neuropathy","Thrombosis","RA Complications",[267,268,269,270],"Rheumatoid Arthritis","generative AI","large language model","Rheumatoid arthritis complications","2025-12-22",{"date":273,"type":34},"2025-12-24",{"date":275,"type":34},"2025-10-01",{"date":277,"type":18},"2026-06",{"name":279,"class":41},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences",{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":287,"sex":288,"minAge":78,"maxAge":289,"enrollmentInfo":290,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":292,"conditions":293,"keywords":298,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":42},"100491380","exploring-immunological-markers-associated-with-mental-fatigue-in-graves-disease-100491380","NCT05678374","Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease","Exploring Immunological Markers in Blood and Cerebrospinal Fluid Associated With Mental Fatigue in Euthyroidism After Graves' Disease- a Cross Sectional Study","Inclusion Criteria\n\n* If patient: Graves' disease with positive TSH-receptor antibodies and thyroid hormones above the upper reference limit at diagnosis\n* Diagnosis15 to 60 months ago. If recidive both episodes must have occurred within 15 months to 60 months.\n* Thyroid hormones within normal range without anti thyroid drugs\n* If control: No thyroid disease\n* Patient and control without mental fatigue: Mental Fatigue Score ≤8 (cut off 10.5)\n* Patient with mental fatigue: Mental Fatigue Score \\>13 and debut of symptoms of mental fatigue in parallel with debut of Graves' disease, without other obvious cause\n\nExclusion Criteria\n\n* Person unable to follow protocol\n* Multiple sclerosis, myalgic encephalomyelitis\u002Fchronic fatigue syndrome, any other neurological disease\n* Traumatic brain injury with unconsciousness\n* Other disease strongly associated with fatigue\n* Pregnancy and breast-feeding\n* On-going or recent systemic treatment with steroids\n* Radioiodine therapy within the last 18 months",true,"FEMALE","72 Years",{"count":291,"type":18},180,"Mental fatigue occurs in many diseases and the reasons are mostly unknown. The investigators hypothesize that remaining mental fatigue after restored hyperthyroidism in Graves' disease is an autoimmune complication. The aim of this study is to explore immunological markers possibly associated with mental fatigue in Graves' disease, which the investigators plan to validate in another study (ImmunoGraves wp 2).\n\nUsing a cross-sectional study design, mental fatigue is scored using a questionnaire to find 60 patients with and 60 without mental fatigue 15-60 months after diagnosis of Graves disease. The patients and 60 thyroid healthy controls without mental fatigue are assessed for thyroid hormones, quality of life, anxiety and depression, self-evaluated stress, coping strategies, eye symptoms and background variables. SciLifeLab in Stockholm, the national facility for autoimmune profiling, has pre-set large arrays including 42000 human proteins. Serum and cerebrospinal fluid will be separately pooled and analysed for a subgroup of patients with or without mental fatigue and for a subgroup of the control group. Proteins that preferably bind to antibodies in sera and\u002For cerebrospinal fluid from Graves' patients with mental fatigue in comparison to non-mental fatigue patients, will be screened against the Human Protein Atlas and the Allen brain map to identify those proteins that are expressed in the brain. Antibodies at higher concentration in the mental fatigue pools compared to the group without mental fatigue will be selected for further analyses on an individual level in the whole cohort together with antibodies targeting g-protein coupled receptors, thyroid autoantibodies, cytokines and biomarkers indicating organic and structural nerve damage.",[294,295,296,297,24],"Graves Disease","Graves Ophthalmopathy","Mental Fatigue","Autoimmune Diseases",[299,300],"Biomarkers","Cerebrospinal fluid in Graves' disease","2025-09-23",{"date":303,"type":34},"2025-09-29",{"date":305,"type":34},"2019-10-01",{"date":307,"type":18},"2028-12-20",{"name":309,"class":310},"Vastra Gotaland Region","OTHER_GOV",{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":78,"enrollmentInfo":318,"targetDuration":4,"studyType":81,"phases":320,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":333},"100582518","prospective-evaluation-of-optithydose-100582518","NCT06864351","Prospective Evaluation of OptiThyDose","Prospective Evaluation of OptiThyDose, a Mathematical Model for Calculating Appropriate Dose Ranges in Children With Thyroid Diseases","Inclusion Criteria:\n\nCongenital hypothyroidism (CH)\n\n* Newborns with pathological neonatal screening and confirmation of an increased Thyrotropin (TSH) level in an independent venous blood sample\n\nGraves' disease (GD)\n\n* Children until 18 years with new diagnosis of GD, recurrence of GD, or insufficiently controlled GD under CMZ\u002FMMZ during follow-up according to:\n\n  * Pathological lab values (suppressed TSH, increased thyroid hormone levels, positive Anti-TSH-receptor antibodies)\n  * Typical clinical picture, if present (goitre, tachycardia, palpitations, weight loss, hyperphagia, altered mood)\n\nCH and GD\n\n* The study participant must be accessible for scheduled visits, treatment and follow-up.\n* Signed Informed Consent form (ICF) obtained prior to any study related procedure. Written IC for study participation must be signed and dated by the patient and\u002For his\u002Fher legal representative(s) in accordance with national legal requirements\n\nExclusion Criteria:\n\nCH and GD\n\n* Exclusion of newborns from mothers with GD\n* Exclusion of patients in case of a life-threatening event\n\nGD\n\n* Exclusion of children with known other aetiologies of hyperthyroidism than GD without elevated Anti-TSH-receptor antibodies e.g.:\n\n  * known toxic thyroid nodules proven by ultrasound\u002Fscintigraphy\n  * known amiodarone induced hyperthyroidism\n  * known McCune Albright syndrome (based on clinical, laboratory, and genetic diagnosis) associated hyperthyroidism\n  * known genetically proven hyperthyroidism caused by activating mutations of the TSH receptor gene",{"count":319,"type":18},150,[83],"The aim of this multicentric, randomised, two-arms and single-blinded clinical trial is to prospectively evaluate OptiThyDose for Congenital hypothyroidism (CH) and Graves' disease (GD).",[24,323,294],"Congenital Hypothyroidism","2025-09-01",{"date":326,"type":34},"2025-09-03",{"date":328,"type":34},"2025-08-28",{"date":330,"type":18},"2029-02",{"name":332,"class":41},"University Children's Hospital Basel",2,{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":287,"sex":15,"minAge":78,"maxAge":4,"enrollmentInfo":341,"targetDuration":343,"studyType":20,"phases":4,"briefSummary":344,"conditions":345,"keywords":355,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":42},"100596262","cardiovascular-kidney-metabolic-syndrome-in-shanghai-zicitizens-100596262","NCT07043166","Cardiovascular-Kidney-Metabolic Syndrome in Shanghai Zicitizens","Epidemiological Survey and Follow-up of Cardiovascular-Kidney-Metabolic Diseases Among Adults in Shanghai","Inclusion Criteria:\n\n1. The 4,094 residents of Shanghai communities who have been enrolled in the STONE cohort.\n2. Individuals who completed the baseline questionnaire survey, physical examination, and related clinical tests between 2016 and 2017, with complete data records.\n3. Willingness to participate in this follow-up study and provision of informed consent.\n\nExclusion Criteria:\n\n1. Participants who have moved away from their original community and have been living elsewhere for more than two years.\n2. Participants whose contact information has changed or become invalid, resulting in loss of contact (those who remain uncontactable after three attempts to reach out).",{"count":342,"type":18},4094,"10 Years","The main purpose of this study is to conduct follow-up assessments and update the cardiorenal outcomes among the STONE cohort that was established during 2016-2017. The secondary aim is to compare metabolic risk factors, metabolic disturbances, and clinically relevant metabolic outcomes between the follow-up period and the baseline assessment. The exploratory goal is to examine the relationships between changes in risk factors and clinical outcomes in the participants.\n\nThe study is planned to begin in May 2025 and will finalize the data collection for the entire population by June 2026. During this time, participants will be categorized based on CKM staging. The follow-up phase will continue until 2035.",[346,347,348,349,350,24,351,352,353,354],"Metabolic Syndrome","Diabetes","Obesity and Overweight","Hypertension","Dyslipidemia","Bone Metabolism Disorder","Chronic Kidney Disease(CKD)","Cardiovascular Diseases (CVD)","Cardiovascular-kidney-metabolic Syndrome",[356,357,358,359,360,361],"Cardiovascular-Kidney-Metabolic Syndrome","metabolic disorders","screening","risk factor","evaluation","prediction","2025-08-31",{"date":364,"type":34},"2025-09-08",{"date":366,"type":34},"2025-07-01",{"date":368,"type":18},"2035-12-31",{"name":370,"class":41},"Shanghai Changzheng Hospital",{"id":372,"slug":373,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":11,"sex":15,"minAge":78,"maxAge":379,"enrollmentInfo":380,"targetDuration":4,"studyType":81,"phases":382,"briefSummary":383,"conditions":384,"keywords":389,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":42},"100573896","phase-3-prophylactic-radiotherapy-optimization-for-enhanced-thyroid-function-protection-in-npc-100573896","NCT06752239","Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC","Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in Nasopharyngeal Carcinoma (PROTECT-NPC): A Multicenter, Non-Inferiority, Open-Label, Randomized Controlled Phase III Clinical Trial","PROTECT-NPC","Inclusion Criteria:\n\n1\\. Male or female, aged 18-70 years; 2. Pathologically confirmed nasopharyngeal carcinoma; 3. No positive lymph nodes in unilateral or bilateral regions III and IVa; 4. Clinical stage I-IVa (AJCC\u002FUICC 8th edition), with no evidence of distant metastasis; 5. Normal thyroid function; 6. ECOG performance status of 0-1; 7. Treatment-naïve patients who have not received any prior antitumor therapy; 6. No contraindications to radiotherapy or chemotherapy; 9. Adequate organ function, meeting the following criteria: Hematologic criteria: WBC ≥ 4.0 × 10⁹\u002FL, ANC ≥ 1.5 × 10⁹\u002FL, PLT ≥ 100 × 10⁹\u002FL, HGB ≥ 90 g\u002FL (no transfusion, blood products, or hematopoietic growth factors used within the past 7 days); Biochemical criteria: ALT and AST \\\u003C 1.5 × ULN, ALP \\\u003C 2.5 × ULN, total bilirubin \\\u003C ULN, BUN and creatinine ≤ 1.5 × ULN or creatinine clearance rate ≥ 60 mL\u002Fmin (calculated using the Cockcroft-Gault formula).\n\n10\\. Voluntarily agreed to participate in the study, signed the informed consent form, demonstrated good compliance, and agreed to follow-up.\n\nExclusion Criteria:\n\n1. History of other malignant tumors (excluding basal cell carcinoma\u002Fsquamous cell carcinoma of the skin or cervical carcinoma in situ);\n2. History of radiotherapy (excluding radiotherapy outside the planned target area for conditions such as melanoma);\n3. History of neck surgery;\n4. Any severe comorbidities that may pose risks to the study or affect compliance, such as unstable heart disease requiring treatment, kidney disease, chronic hepatitis, poorly controlled diabetes (fasting blood glucose \\> 1.5 × ULN), or psychiatric disorders;\n5. History of hyperthyroidism, hypothyroidism, or immune-related thyroid disorders;\n6. Other family or social factors, as judged by the investigator, may force the study's early termination, compromise patient safety, or affect the collection of trial data.","70 Years",{"count":381,"type":18},474,[198],"This study is a multicenter, non-inferiority, open-label, randomized controlled Phase III clinical trial. It aims to compare the efficacy of modified delineation radiotherapy (experimental group) versus standard delineation radiotherapy (control group) in the prophylactic irradiation of neck lymphatic drainage areas III\u002FIVa in nasopharyngeal carcinoma. The study evaluates the incidence of primary hypothyroidism, quality of life, and adverse events between the two groups.",[385,386,24,387,388],"Nasopharyngeal Carcinoma","Quality of Life","Radiotherapy Side Effect","Radiotherapy",[385,386,390,388],"Thyroid Function Protection","2025-04-08",{"date":393,"type":34},"2025-04-10",{"date":395,"type":34},"2025-01-01",{"date":397,"type":18},"2031-12-31",{"name":399,"class":41},"Jiangxi Provincial Cancer Hospital",{"id":401,"slug":402,"hasResults":11,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":11,"sex":15,"minAge":78,"maxAge":4,"enrollmentInfo":407,"targetDuration":4,"studyType":81,"phases":409,"briefSummary":411,"conditions":412,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":429,"locationsCount":333},"100524715","phase-2-extension-study-of-two-doses-of-linsitinib-in-subjects-with-active-moderate-to-severe-thyroid-eye-disease-ted-100524715","NCT06112340","Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)","A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)","Inclusion Criteria:\n\n* Subject who completed the 24-week double-mask period of VGN-TED-301 and are proptosis non-responders (\\\u003C 2 mm reduction in proptosis in the study eye) at Week 24 of VGN-TED-301 study or proptosis responders at Week 24 who relapse during the Follow-Up period of VGN-TED-301\n* Subject has not received any treatment for TED since Week 24 of VGN-TED-301\n* Subjects must be euthyroid with the participant's baseline disease under control or have mild hypo- or hyperthyroidism (defined as free thyroxine \\[FT4\\] and free triiodothyronine levels \\[FT3\\] \\\u003C50% above or below the normal limits) at Baseline. Every effort should be made to correct mild hypo- or hyperthyroidism promptly and maintain the euthyroid state for the duration of the clinical trial\n* Does not require immediate ophthalmic surgery, radiotherapy to orbits or other ophthalmological intervention at the time of Baseline and is not planning for any such treatment during the course of the study\n\nExclusion Criteria:\n\n* The exclusion criteria of protocol VGN-TED-301 also apply to this extension study.",{"count":408,"type":18},75,[410,198],"PHASE2","The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.",[413,414,415,416,417,295,24,418,419,420,421,422],"Thyroid Eye Disease","Graves Orbitopathy","Endocrine System Diseases","Eye Diseases","Thyroid Associated Ophthalmopathy","Orbital Diseases","Proptosis","IGF1R","Exophthalmos","Hashimoto","2025-02-24",{"date":425,"type":34},"2025-02-25",{"date":427,"type":34},"2023-10-11",{"date":277,"type":18},{"name":430,"class":431},"Sling Therapeutics, Inc.","INDUSTRY"]